TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will host a virtual key opinion leader event on December 8, 2025 at 8:00 a.m. ET to discuss updated data from the ALLOHA™ Phase 1 trial and the market opportunity for its heme program.

The event will review a poster presented at the 67th ASH Annual Meeting, including two-year relapse data from initial patients in the ALLOHA trial of TSC-101 in heme malignancy patients undergoing allogeneic HCT, the company’s newly implemented commercial-ready manufacturing process, and plans for a pivotal trial slated to start in Q2 2026. A replay will be available on the company’s Events and Presentations page.

Insights

Clinical development and commercial strategy expert

Updated two-year relapse data and a commercial-ready manufacturing process precede a planned pivotal trial in Q2 2026.

The announcement centers on updated clinical data from the ALLOHA Phase 1 trial and a planned discussion of those results at a virtual KOL event on December 8, 2025. The content confirms presentation of two-year relapse data on initial patients treated with TSC-101 after allogeneic HCT and states an improved, commercial-ready manufacturing process has been implemented in the ongoing Phase 1 trial.

These facts imply tangible clinical and operational progress: two-year relapse outcomes represent a concrete efficacy/timepoint metric, and an implemented manufacturing process is an explicit operational milestone tied to trial scalability. Key dependencies and risks remain the content not disclosing the actual relapse rates, safety details, or regulatory feedback; those items materially affect interpretation of the clinical signal and commercial viability. Watch for the detailed poster data release and the company’s description of safety and durability metrics at the virtual event and in the ASH poster, and for enrollment and regulatory milestones tied to the planned pivotal trial start in Q2 2026.

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET.

The event will provide an in-depth review of the poster presented at the ASH Annual Meeting, including two-year relapse data on initial patients from TScan’s ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The Company will discuss its improved commercial-ready manufacturing process that has recently been implemented in the ALLOHA Phase 1 trial and will be used in the upcoming pivotal trial scheduled to start in the second quarter of 2026. The Company will also review the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.

Featured speakers include:

• Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Director of the Cell Therapy Program, Columbia University Irving Medical Center
  
• Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
  
• Stephen Camiolo, Senior Vice President, Market Access, TScan Therapeutics
  

Registration for the live event can be found here. A replay will be made available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their TargetScan platform to discover novel targets in various T cell-mediated autoimmune disorders.

Contacts

Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
tneubecker@tscan.com

Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When will TScan (TCRX) host the virtual KOL event to discuss ALLOHA Phase 1 updates?

The virtual event will be held on December 8, 2025 at 8:00 a.m. ET.

What ALLOHA Phase 1 data will TScan (TCRX) review at the December 8, 2025 event?

The company will review the ASH poster including two-year relapse data from initial ALLOHA patients treated with TSC-101.

How will TScan (TCRX) use its new manufacturing process discussed at the KOL event?

TScan said the improved commercial-ready manufacturing process is implemented in ALLOHA and will be used in the pivotal trial starting Q2 2026.

Who are the featured speakers for TScan's December 8, 2025 virtual event?

Featured speakers include Ran Reshef, M.D., Gavin MacBeath, Ph.D., and Stephen Camiolo.

Where can investors access the TScan (TCRX) live event and replay for the ALLOHA update?

Registration is available via the company website and a replay will be posted in the Events and Presentations section at ir.tscan.com.

What key development timeline did TScan (TCRX) disclose for TSC-101 in heme malignancies?

TScan indicated the pivotal trial is scheduled to start in Q2 2026.